Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emek Kocaturk

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Cutaneous and Ocular Toxicology|July 2, 2021
A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticariaSinem Ornek, Emek Kocaturk
Asia Pacific Allergy|May 9, 2014
Omalizumab in recurring larynx angioedema: a case reportAyse Bilge Ozturk, Emek Kocaturk
Anais Brasileiros De Dermatologia|March 17, 2017
Follicular traction urticariaHatice Duman, Ilteris Oguz Topal, Emek Kocaturk
Allergology International : Official Journal of the Japanese Society of Allergology|June 25, 2014
Successful treatment of a bullous urticaria with omalizumabAyse Bilge Ozturk, Emek Kocaturk, Erman Ozturk
The Journal of Allergy and Clinical Immunology. in Practice|March 3, 2023
Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity, and AutoallergyRiccardo Asero, Marta Ferrer, Emek Kocaturk, et al.
Journal of Cutaneous Pathology|November 7, 2023
TOX, TWIST1, STAT4, and SATB1 protein expressions in early-stage mycosis fungoidesSinem Örnek, Selver Ozekinci, Tugba Ipin, et al.
Indian Journal of Dermatology, Venereology and Leprology|June 1, 2016
Oleogranulomas of the breast treated with hydroxychloroquineIlteris Oguz Topal, Emek Kocaturk, Hatice Duman, et al.
Qatar Medical Journal|August 15, 2022
Chronic urticaria and COVID-19 vaccination: Qatar data (preliminary report of COVAC-CU-international)Saleema Purayil, Sherin Thalappil, Maryam Al-Nesf, et al.
Asian Pacific Journal of Allergy and Immunology|February 27, 2021
Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticariaPelin Kuteyla Can, Piril Etikan, Ece Nur Degirmentepe, et al.
International Immunopharmacology|September 17, 2022
An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticariaSinem Ayse Ornek, Cihan Orcen, Martin K Church, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Cutaneous and Ocular Toxicology|July 2, 2021
A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticariaSinem Ornek, Emek Kocaturk
Asia Pacific Allergy|May 9, 2014
Omalizumab in recurring larynx angioedema: a case reportAyse Bilge Ozturk, Emek Kocaturk
Anais Brasileiros De Dermatologia|March 17, 2017
Follicular traction urticariaHatice Duman, Ilteris Oguz Topal, Emek Kocaturk
Allergology International : Official Journal of the Japanese Society of Allergology|June 25, 2014
Successful treatment of a bullous urticaria with omalizumabAyse Bilge Ozturk, Emek Kocaturk, Erman Ozturk
The Journal of Allergy and Clinical Immunology. in Practice|March 3, 2023
Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity, and AutoallergyRiccardo Asero, Marta Ferrer, Emek Kocaturk, et al.
Journal of Cutaneous Pathology|November 7, 2023
TOX, TWIST1, STAT4, and SATB1 protein expressions in early-stage mycosis fungoidesSinem Örnek, Selver Ozekinci, Tugba Ipin, et al.
Indian Journal of Dermatology, Venereology and Leprology|June 1, 2016
Oleogranulomas of the breast treated with hydroxychloroquineIlteris Oguz Topal, Emek Kocaturk, Hatice Duman, et al.
Qatar Medical Journal|August 15, 2022
Chronic urticaria and COVID-19 vaccination: Qatar data (preliminary report of COVAC-CU-international)Saleema Purayil, Sherin Thalappil, Maryam Al-Nesf, et al.
Asian Pacific Journal of Allergy and Immunology|February 27, 2021
Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticariaPelin Kuteyla Can, Piril Etikan, Ece Nur Degirmentepe, et al.
International Immunopharmacology|September 17, 2022
An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticariaSinem Ayse Ornek, Cihan Orcen, Martin K Church, et al.
Pageof 6